POWERbreathe IMT is Beneficial for Patients with Asthma

POWERbreathe Inspiratory Muscle Training is clinically proven to be beneficial for patients with asthma.

POWERbreathe Medic IMT available for prescription in the UK

After 20 months of rigorous assessment, the POWERbreathe Medic IMT device was made available in the UK for prescription in the National Health Service (NHS) Drug Tariff: PIP 232-1040. It found that the POWERbreathe Medic offers people with asthma a drug-free and clinically-proven method to reduce symptoms and put them in control of their asthma.

POWERbreathe Medic IMT rigorously assessed

Although the role of IMT in the management of asthma has been less widely studied than in COPD, data exists from five randomised controlled trials that are unanimously supportive of IMT in the management of asthma.

Asthma patients benefit from POWERbreathe Medic IMT

After as little as 3 weeks’ POWERbreathe training, patients experience a reduction in dyspnoea, the medical term for breathlessness or shortness of breath, as well as improvements in quality of life. Most striking however are the observations that longer-term IMT (6 months) reduces absence from school/work (by ~95%), use of healthcare resources (by ~75%), and the consumption of medication (by ~79%).

The five randomised controlled clinical trials in support of POWERbreathe IMT

  1. Inspiratory muscle training improves lung function and reduces exertional dyspnoea in mild/moderate asthmatics - McConnell, A. K., M. P. Caine, et al. (1998). Clinical Science 95(2): 4P.
  2. Inspiratory muscle training in patients with bronchial asthma 
  3. Specific inspiratory muscle training in patients with mild asthma with high consumption of inhaled beta(2)-agonists
  4. The relationship among inspiratory muscle strength, the perception of dyspnea and inhaled beta2-agonist use in patients with asthma
  5. Influence of gender and inspiratory muscle training on the perception of dyspnea in patients with asthma

Leave a Comment

Sorry, you must be logged in to post a comment.